Madrigal Pharmaceuticals, Inc. - Understand $mdgl stock

$MDGL Market Cap: $6.946 Billion

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$76.81M

TTM

Gross Margin

96.1%

TTM

Net Earnings

-$518.6M

TTM

Current Assets

$1.064B

Q3 2024

Current Liabilities

$177.8M

Q3 2024

Current Ratio

598.08%

Q3 2024

Total Assets

$1.073B

Q3 2024

Total Liabilities

$296.1M

Q3 2024

Book Value

$777.2M

Q3 2024

Cash

$232.7M

Q3 2024

P/E

-13.39

Nov 29, 2024 EST

Free Cash Flow

-$438.3M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003
Revenue	$0.00		$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$147.0K	$853.0K	$978.0K	$144.2M	$2.600M	$700.0K	$0.00	$0.00	$200.0K	$1.300M
YoY Change											-100.0%	-82.77%	-12.78%	-99.32%	5446.15%	271.43%			-100.0%	-84.62%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$147.0K	$853.0K	$978.0K	$144.2M	$2.600M	$700.0K	$0.00	$0.00	$200.0K	$1.300M
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003
Selling, General & Admin	$108.1M	$48.13M	$37.32M	$21.90M	$22.60M	$15.30M	$7.700M	$9.300M	$800.0K	$15.70M	$15.70M	$11.70M	$11.60M	$11.40M	$12.70M	$14.70M	$14.90M	$8.600M	$11.30M	$7.400M	$5.300M
YoY Change	124.7%	28.97%	70.4%	-3.1%	47.71%	98.7%	-17.2%	1062.5%	-94.9%	0.0%	34.19%	0.86%	1.75%	-10.24%	-13.61%	-1.34%	73.26%	-23.89%	52.7%	39.62%	-51.38%
% of Gross Profit
Research & Development	$272.4M	$245.4M	$205.2M	$184.8M	$72.30M	$25.40M	$24.40M	$15.90M	$2.400M	$68.20M	$71.90M	$49.41M	$41.46M	$40.25M	$51.05M	$81.60M	$52.00M	$50.50M	$59.90M	$38.10M	$24.30M
YoY Change	10.96%	19.63%	11.02%	155.6%	184.65%	4.1%	53.46%	562.5%	-96.48%	-5.15%	45.51%	19.17%	3.01%	-21.16%	-37.43%	56.92%	2.97%	-15.69%	57.22%	56.79%	232.88%
% of Gross Profit
Depreciation & Amortization	$527.0K	$467.0K	$405.0K	$470.0K	$110.0K	$100.0K	$80.00K	$0.00	$0.00	$670.0K	$516.0K	$738.0K	$1.464M	$1.933M	$2.463M	$2.720M	$3.350M	$3.660M	$2.460M	$1.550M	$1.010M
YoY Change	12.85%	15.31%	-13.83%	327.27%	10.0%	25.0%			-100.0%	29.84%	-30.08%	-49.59%	-24.26%	-21.52%	-9.45%	-18.81%	-8.47%	48.78%	58.71%	53.47%	248.28%
% of Gross Profit
Operating Expenses	$380.5M	$293.6M	$242.5M	$206.7M	$95.00M	$40.70M	$32.10M	$25.20M	$3.200M	$84.00M	$87.56M	$49.41M	$53.02M	$51.70M	$64.94M	$96.30M	$67.00M	$59.20M	$71.20M	$45.50M	$29.60M
YoY Change	29.61%	21.07%	17.31%	117.58%	133.42%	26.79%	27.38%	687.5%	-96.19%	-4.06%	77.2%	-6.8%	2.54%	-20.39%	-32.56%	43.73%	13.18%	-16.85%	56.48%	53.72%	62.64%
Operating Profit	-$380.5M	-$293.6M	-$242.5M	-$206.7M							-$87.56M	-$60.94M	-$45.43M	-$36.90M	$79.30M
YoY Change	29.61%	21.07%	17.33%								43.68%	34.14%	23.13%	-146.53%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003
Interest Expense	$12.71M	$3.964M	$363.0K	$4.300M	$11.00M	$7.700M	$600.0K	-$1.200M	-$3.600M	-$2.200M	-$2.633M	-$1.849M	-$1.948M	-$569.0K	-$216.0K	$1.100M	$2.700M	$1.900M	$2.300M	$1.000M	$400.0K
YoY Change	220.69%	992.01%	-91.56%	-60.91%	42.86%	1183.33%	-150.0%	-66.67%	63.64%	-16.45%	42.4%	-5.08%	242.36%	163.43%	-119.64%	-59.26%	42.11%	-17.39%	130.0%	150.0%	300.0%
% of Operating Profit															-0.27%
Other Income/Expense, Net	$0.00	$0.00	$273.0K	$100.0K	$0.00	$200.0K	$400.0K
YoY Change		-100.0%	173.0%		-100.0%	-50.0%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003
Pretax Income	-$373.6M	-$295.4M	-$241.8M	-$202.2M	-$83.90M	-$32.80M	-$31.20M	-$26.40M	-$6.800M	-$86.20M	-$90.20M	-$62.80M	-$47.40M	-$37.50M	$79.10M	-$92.60M	-$63.50M	-$57.30M	-$68.90M	-$45.90M	-$27.90M
YoY Change	26.5%	22.12%	19.61%	141.0%	155.79%	5.13%	18.18%	288.24%	-92.11%	-4.43%	43.63%	32.49%	26.4%	-147.41%	-185.42%	45.83%	10.82%	-16.84%	50.11%	64.52%	-22.93%
Income Tax	$0.00	$0.00		$0.00	$0.00	$0.00	$0.00			$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
% Of Pretax Income															0.0%
Net Earnings	-$373.6M	-$295.4M	-$241.8M	-$202.2M	-$83.90M	-$32.80M	-$31.20M	-$26.40M	-$6.800M	-$86.20M	-$90.20M	-$62.80M	-$47.40M	-$37.50M	$79.10M	-$92.60M	-$63.50M	-$57.30M	-$68.90M	-$45.90M	-$27.90M
YoY Change	26.47%	22.14%	19.61%	141.0%	155.79%	5.13%	18.18%	288.24%	-92.11%	-4.43%	43.63%	32.49%	26.4%	-147.41%	-185.42%	45.83%	10.82%	-16.84%	50.11%	64.52%	-22.93%
Net Earnings / Revenue												-42721.09%	-5556.86%	-3834.36%	54.85%	-3561.54%	-9071.43%			-22950.0%	-2146.15%
Basic Earnings Per Share	-$19.99	-$17.23	-$14.63	-$13.09									-$1.00	-$0.93	$2.33
Diluted Earnings Per Share	-$19.99	-$17.23	-$14.63M	-$13.13M	-$5.448M	-$2.216M	-$2.557M	-$5.077M	-$1.133M	-$30.79M	-$45.10M	-$36.94M	-$1.00	-$0.93	$2.32	-$92.60M	-$70.56M	-$95.50M	-$114.8M	-$91.80M	-$27.90M

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003
Cash & Short-Term Investments	$634.1M	$358.8M	$270.3M	$284.1M	$439.0M	$483.7M	$191.5M	$40.50M	$300.0K	$97.70M	$91.50M	$100.6M	$39.70M	$51.00M	$44.20M	$73.60M	$115.6M	$46.80M	$62.10M	$125.0M	$76.20M
YoY Change	76.75%	32.71%	-4.84%	-35.28%	-9.24%	152.58%	372.84%	13400.0%	-99.69%	6.78%	-9.05%	153.4%	-22.16%	15.38%	-39.95%	-36.33%	147.01%	-24.64%	-50.32%	64.04%
Cash & Equivalents	$97.19M	$331.5M	$36.27M	$54.00M	$46.70M	$57.40M	$148.6M	$19.10M	$300.0K	$46.00M	$48.50M	$81.50M	$30.10M	$31.30M	$44.20M	$52.00M	$115.6M	$33.70M	$23.80M	$42.70M	$36.10M
Short-Term Investments	$534.2M	$27.23M	$234.1M	$230.1M	$392.3M	$426.3M	$42.90M	$21.40M	$0.00	$51.70M	$43.00M	$19.10M	$9.700M	$19.70M	$0.00	$21.50M	$0.00	$13.10M	$38.20M	$82.20M	$40.20M
Other Short-Term Assets	$3.150M	$2.595M	$1.338M	$1.000M	$1.200M	$1.500M	$500.0K	$700.0K	$100.0K	$1.700M	$800.0K	$800.0K	$600.0K	$400.0K	$400.0K	$1.700M	$1.400M	$800.0K	$900.0K	$1.100M	$800.0K
YoY Change	21.39%	93.95%	33.8%	-16.67%	-20.0%	200.0%	-28.57%	600.0%	-94.12%	112.5%	0.0%	33.33%	50.0%	0.0%	-76.47%	21.43%	75.0%	-11.11%	-18.18%	37.5%
Inventory
Prepaid Expenses
Receivables													$0.00	$100.0K	$0.00	$16.00M	$0.00
Other Receivables													$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$637.3M	$361.4M	$271.7M	$285.2M	$440.2M	$485.2M	$192.0M	$41.20M	$400.0K	$99.30M	$92.20M	$101.4M	$40.30M	$51.50M	$44.60M	$91.20M	$117.0M	$47.60M	$63.00M	$126.0M	$77.10M
YoY Change	76.35%	33.01%	-4.74%	-35.21%	-9.27%	152.71%	366.02%	10200.0%	-99.6%	7.7%	-9.07%	151.61%	-21.75%	15.47%	-51.1%	-22.05%	145.8%	-24.44%	-50.0%	63.42%
Property, Plant & Equipment	$3.266M	$1.203M	$1.648M	$1.800M	$1.900M	$200.0K	$300.0K	$0.00	$0.00	$1.000M	$1.600M	$1.200M	$1.400M	$2.200M	$4.000M	$5.900M	$5.600M	$6.100M	$8.100M	$4.800M	$3.200M
YoY Change	171.49%	-27.0%	-8.44%	-5.26%	850.0%	-33.33%			-100.0%	-37.5%	33.33%	-14.29%	-36.36%	-45.0%	-32.2%	5.36%	-8.2%	-24.69%	68.75%	50.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets										$300.0K	$1.400M	$500.0K	$600.0K	$400.0K	$400.0K	$100.0K	$100.0K	$1.100M	$100.0K	$1.200M	$100.0K
YoY Change										-78.57%	180.0%	-16.67%	50.0%	0.0%	300.0%	0.0%	-90.91%	1000.0%	-91.67%	1100.0%
Total Long-Term Assets	$3.266M	$1.203M	$1.648M	$1.800M	$1.900M	$200.0K	$300.0K	$0.00	$0.00	$1.400M	$3.000M	$1.600M	$2.000M	$2.600M	$4.300M	$6.100M	$5.600M	$7.200M	$8.200M	$6.000M	$3.300M
YoY Change	171.49%	-27.0%	-8.44%	-5.26%	850.0%	-33.33%			-100.0%	-53.33%	87.5%	-20.0%	-23.08%	-39.53%	-29.51%	8.93%	-22.22%	-12.2%	36.67%	81.82%
Total Assets	$640.5M	$362.6M	$273.3M	$287.0M	$442.1M	$485.4M	$192.3M	$41.20M	$400.0K	$100.7M	$95.20M	$103.0M	$42.30M	$54.10M	$48.90M	$97.30M	$122.6M	$54.80M	$71.20M	$132.0M	$80.40M
YoY Change
Accounts Payable	$28.04M	$23.83M	$21.38M	$1.000M	$1.200M	$2.500M	$1.900M	$800.0K	$100.0K	$3.100M	$6.600M	$5.700M	$3.500M	$1.900M	$4.000M	$3.300M	$2.500M	$2.600M	$3.400M	$2.900M	$200.0K
YoY Change	17.67%	11.46%	2038.0%	-16.67%	-52.0%	31.58%	137.5%	700.0%	-96.77%	-53.03%	15.79%	62.86%	84.21%	-52.5%	21.21%	32.0%	-3.85%	-23.53%	17.24%	1350.0%
Accrued Expenses	$90.51M	$92.06M	$55.46M	$45.50M	$24.00M	$6.000M	$8.100M	$4.000M	$100.0K	$18.50M	$16.10M	$9.900M	$7.400M	$6.700M	$6.600M	$15.20M	$9.200M	$6.100M	$8.700M	$9.000M	$2.900M
YoY Change	-1.69%	66.0%	21.89%	89.58%	300.0%	-25.93%	102.5%	3900.0%	-99.46%	14.91%	62.63%	33.78%	10.45%	1.52%	-56.58%	65.22%	50.82%	-29.89%	-3.33%	210.34%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$48.60M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change								-100.0%
Long-Term Debt Due										$9.300M	$9.500M	$7.900M	$4.200M	$3.500M	$1.300M	$2.200M	$2.400M	$2.300M	$1.900M	$500.0K	$0.00
YoY Change										-2.11%	20.25%	88.1%	20.0%	169.23%	-40.91%	-8.33%	4.35%	21.05%	280.0%
Total Short-Term Liabilities	$118.5M	$115.9M	$76.84M	$46.60M	$25.10M	$8.400M	$10.10M	$4.800M	$49.30M	$30.90M	$32.20M	$23.50M	$15.10M	$16.70M	$16.50M	$33.30M	$20.80M	$11.50M	$14.50M	$12.90M	$3.500M
YoY Change	2.29%	50.83%	64.89%	85.66%	198.81%	-16.83%	110.42%	-90.26%	59.55%	-4.04%	37.02%	55.63%	-9.58%	1.21%	-50.45%	60.1%	80.87%	-20.69%	12.4%	268.57%
Long-Term Debt	$115.5M	$49.29M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$4.700M	$13.90M	$4.500M	$12.40M	$11.70M	$800.0K	$2.000M	$2.800M	$3.200M	$4.300M	$1.200M	$0.00
YoY Change	134.29%								-100.0%	-66.19%	208.89%	-63.71%	5.98%	1362.5%	-60.0%	-28.57%	-12.5%	-25.58%	258.33%
Other Long-Term Liabilities	$1.186M	$0.00	$387.0K	$500.0K	$400.0K								$0.00	$2.200M	$6.700M	$120.7M	$74.20M	$0.00
YoY Change		-100.0%	-22.6%	25.0%									-100.0%	-67.16%	-94.45%	62.67%
Total Long-Term Liabilities	$116.7M	$49.29M	$387.0K	$500.0K	$400.0K	$0.00	$0.00	$0.00	$0.00	$4.700M	$13.90M	$4.500M	$12.40M	$13.90M	$7.500M	$122.7M	$77.00M	$3.200M	$4.300M	$1.200M	$0.00
YoY Change	136.7%	12636.18%	-22.6%	25.0%					-100.0%	-66.19%	208.89%	-63.71%	-10.79%	85.33%	-93.89%	59.35%	2306.25%	-25.58%	258.33%
Total Liabilities	$235.2M	$165.2M	$77.23M	$47.00M	$25.50M	$8.400M	$10.10M	$4.800M	$49.30M	$35.50M	$46.10M	$28.00M	$27.60M	$30.60M	$24.00M	$156.0M	$97.80M	$14.70M	$18.70M	$14.10M	$3.500M
YoY Change	42.4%	113.9%	64.31%	84.31%	203.57%	-16.83%	110.42%	-90.26%	38.87%	-22.99%	64.64%	1.45%	-9.8%	27.5%	-84.62%	59.51%	565.31%	-21.39%	32.62%	302.86%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2011	2010	2009
Basic Shares Outstanding	18.69M shares	17.14M	16.54M	15.45M	47.20M shares	40.37M shares	33.89M shares
Diluted Shares Outstanding	18.69M shares	17.14M	16.54M	15.45M	47.20M shares	40.37M shares	34.12M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $6.9462 Billion

About MADRIGAL PHARMACEUTICALS, INC.

Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company is headquartered in West Conshohocken, Pennsylvania and currently employs 376 full-time employees. The company went IPO on 2007-02-06. The firm is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The firm's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Company’s clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.

Industry: Pharmaceutical Preparations Peers: Vericel Corp Arcutis Biotherapeutics, Inc. Avid Bioservices, Inc. Avidity Biosciences, Inc. Emergent BioSolutions Inc. ENANTA PHARMACEUTICALS INC Gossamer Bio, Inc. ImmunoGen, Inc. Sana Biotechnology, Inc.